600594 Stock Overview
Researches, develops, produces, and sells pharmaceutical products in China. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Guizhou Yibai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥3.78 |
52 Week High | CN¥5.94 |
52 Week Low | CN¥2.76 |
Beta | 0.38 |
1 Month Change | -3.82% |
3 Month Change | 5.88% |
1 Year Change | -33.57% |
3 Year Change | -53.51% |
5 Year Change | -24.70% |
Change since IPO | 53.71% |
Recent News & Updates
Recent updates
Shareholder Returns
600594 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -8.3% | -1.9% | -0.6% |
1Y | -33.6% | -5.7% | 8.3% |
Return vs Industry: 600594 underperformed the CN Pharmaceuticals industry which returned -5.4% over the past year.
Return vs Market: 600594 underperformed the CN Market which returned 9.2% over the past year.
Price Volatility
600594 volatility | |
---|---|
600594 Average Weekly Movement | 7.2% |
Pharmaceuticals Industry Average Movement | 7.3% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.9% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600594 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600594's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 5,509 | Ya Qi Dou | www.gzcci.com |
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.
Guizhou Yibai Pharmaceutical Co., Ltd. Fundamentals Summary
600594 fundamental statistics | |
---|---|
Market cap | CN¥2.97b |
Earnings (TTM) | -CN¥235.62m |
Revenue (TTM) | CN¥2.40b |
1.2x
P/S Ratio-12.6x
P/E RatioIs 600594 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
600594 income statement (TTM) | |
---|---|
Revenue | CN¥2.40b |
Cost of Revenue | CN¥955.85m |
Gross Profit | CN¥1.44b |
Other Expenses | CN¥1.68b |
Earnings | -CN¥235.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 26, 2025
Earnings per share (EPS) | -0.30 |
Gross Margin | 60.13% |
Net Profit Margin | -9.83% |
Debt/Equity Ratio | 30.3% |
How did 600594 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield-22%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 16:04 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guizhou Yibai Pharmaceutical Co., Ltd. is covered by 20 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Shuchang Liu | Changjiang Securities Co. LTD. |
Chi Man Wong | China Galaxy International Securities (Hong Kong) |
Haigang Chen | China International Capital Corporation Limited |